Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CD200 receptor 1 (CD200R1) is a cell surface transmembrane glycoprotein that acts as an inhibitory receptor on myeloid lineage cells and some T-cell subsets. Upon binding to its ligand CD200, it downregulates pro-inflammatory signaling, including the inhibition of TNF-alpha, interferons, and iNOS. Dysregulation of this pathway is implicated in inflammatory diseases, and some pathogens exploit it to suppress host immune defenses.
Inhibition of pro-inflammatory signaling via DOK2 adaptor recruitment and downstream pathway activation upon CD200 binding.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CD200 Receptor 1 (CD200R1).